Targeting CSPG4 enhances the anti-tumor activity of CAR-NK cells for glioblastoma.

ABSTRACT:

Purpose

Glioblastoma (GBM), an aggressive brain malignancy with high recurrence rates and suboptimal response to conventional therapies, necessitates novel treatment strategies. Chimeric antigen receptor natural killer (CAR-NK) cell therapy represents a promising immunotherapeutic approach. CSPG4 (chondroitin sulfate proteoglycan 4), a tumor-associated antigen overexpressed in GBM and critically involved in tumor proliferation and metastasis, was investigated as a therapeutic target. This study aimed to evaluate the efficacy of CSPG4-targeted CAR-NK cells in GBM treatment.

Methods and results

We engineered a second-generation CAR construct incorporating the CSPG4-specific scFv 763.74, a CD8 transmembrane domain, and intracellular co-stimulatory/activation domains from CD28 a

SUBMITTER: Xiong Q 

PROVIDER: S-EPMC12528275 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature